Invivyd Shares Surge 26.8% on Institutional Stakes and VYD2311 IND Clearance

Introduction

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company founded in 2020 and headquartered in New Haven, Connecticut. The company develops monoclonal antibodies aimed at addressing viral evolution, starting with SARS-CoV-2 and expanding into influenza and other high-need indications. Invivyd utilizes a proprietary integrated technology platform that incorporates evolutionary virology, predictive modeling, and antibody engineering to create candidates for both the prevention and treatment of infectious diseases.

Corporate Structure

Invivyd operates with a workforce of 51–200 employees, contributing to research, development, manufacturing, and commercial functions. In March 2024, the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for Invivyd’s first monoclonal antibody. On September 18, 2025, Paul Bolno, President and CEO of Wave Life Sciences, joined Invivyd’s board of directors.

Monoclonal Antibody by Bilal O.

Recent Developments and News

In March 2024, Invivyd received EUA for its lead antibody candidate targeting SARS-CoV-2.
On October 18, 2025, the company sponsored the Immune Deficiency Foundation Meeting for Primary Immunodeficiency in Seattle, engaging with patient communities.
In October 2025, Invivyd secured IND clearance and alignment with the FDA for its investigational antibody VYD2311, which is part of its pivotal clinical program, REVOLUTION.
During IDWeek 2025 in November 2025, Invivyd presented at Booths 520 & 521.
On November 14, 2025, three separate Schedule 13G/A filings reported institutional holdings: Point72 Asset Management and affiliates revealed ownership of 20,372,479 shares (9.7%), while Janus Henderson Group PLC and Janus Henderson Biotech Innovation Master Fund Ltd disclosed combined ownership of approximately 46,959,222 shares (22.4%).

Financial and Strategic Aspects

As of November 17, 2025, IVVD closed at $2.9799, reflecting a 26.80% increase on a volume of 4,189,049 shares. The company’s intraday market capitalization was approximately $547.8 million.
For the trailing twelve months ending September 30, 2025, Invivyd reported revenue of $50.04 million and a net loss of $59.86 million, translating to a diluted EPS of –$0.45. The balance sheet showed $84.97 million in cash and a debt/equity ratio of 2.88%. Valuation multiples included a price/sales ratio of 6.23 and a price/book ratio of 5.89, reflecting the company’s focus on pipeline development and clinical research.

Market Position and Industry Context

Invivyd operates within the competitive landscape of antibody-based therapeutics, positioned alongside companies developing vaccines, small-molecule antivirals, and other monoclonal antibodies. Its proprietary platform is aimed at delivering candidates that maintain efficacy against emerging variants. By targeting immunocompromised populations and using real-time viral monitoring, Invivyd is positioned to navigate the complexities of a rapidly evolving market.

tl;dr

• On November 17, 2025, IVVD shares increased 26.80% to $2.9799 amid significant volume following disclosures of institutional stakes by Point72 and Janus Henderson.
• In October 2025, Invivyd received IND clearance and FDA alignment for VYD2311 under its REVOLUTION clinical program.
• Events on October 18, 2025 (IDF Meeting) and November 2025 (IDWeek) underscored patient engagement and partnerships in research.
• Institutional filings on November 14, 2025 indicated notable investor holdings, with 9.7% ownership by Point72 affiliates and 22.4% by Janus Henderson entities.